Travere Therapeutics, Inc. reported significant financial growth in its latest quarterly results, with total revenue reaching $164.9 million for the three months ended September 30, 2025, compared to $62.9 million for the same period in 2024. This represents a 162% increase year-over-year, driven primarily by a substantial rise in net product sales of FILSPARI, which amounted to $90.9 million, up from $35.6 million in the prior year. The company also recognized $51.7 million in license and collaboration revenue, a notable increase from $1.9 million in the previous year, largely due to a $40 million market access milestone associated with its collaboration with CSL Vifor.
In terms of profitability, Travere reported an operating income of $24.9 million for the third quarter of 2025, a significant turnaround from an operating loss of $56.1 million in the same quarter of 2024. The net income for the quarter was $25.7 million, compared to a net loss of $54.8 million in the prior year. For the nine months ended September 30, 2025, the company recorded a net loss of $28.3 million, a substantial improvement from a loss of $261.3 million during the same period in 2024.
Operationally, Travere has made strategic advancements, including the full approval of FILSPARI by the FDA in September 2024 for the treatment of primary Immunoglobulin A nephropathy (IgAN). The company has also expanded its market presence in Europe, with FILSPARI becoming commercially available under conditional marketing authorization in August 2024. Additionally, Travere entered into a licensing agreement with Renalys Pharma in January 2024 to develop and commercialize sparsentan in Japan and other Asian markets, further broadening its geographic reach.
As of September 30, 2025, Travere's total assets were reported at $538.6 million, a decrease from $594.1 million at the end of 2024, primarily due to a reduction in marketable debt securities. The company’s cash and cash equivalents increased to $110.9 million, up from $58.5 million at the end of 2024. The workforce has also expanded, with the company employing a total of 89,456,626 shares outstanding as of the reporting date. Looking ahead, Travere anticipates continued growth driven by the commercialization of FILSPARI and the potential approval of sparsentan for focal segmental glomerulosclerosis (FSGS), with a Prescription Drug User Fee Act (PDUFA) target action date set for January 13, 2026.
About Travere Therapeutics, Inc.
Travere Therapeutics is a biopharmaceutical company focused on developing and commercializing therapies for rare kidney and metabolic diseases. Its core products include FILSPARI (sparsentan) for IgA nephropathy and FSGS, and pegtibatinase for homocystinuria. The company leverages clinical expertise, innovative pipeline development, and strategic licensing to address significant unmet medical needs in niche markets worldwide.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.